{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:56:25Z","timestamp":1781528185590,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21CIII\/00025"],"award-info":[{"award-number":["PI21CIII\/00025"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19CIII\/00004 \\u2013JA-"],"award-info":[{"award-number":["PI19CIII\/00004 \\u2013JA-"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.eclinm.2022.101542","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T17:34:31Z","timestamp":1656696871000},"page":"101542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9159-3520","authenticated-orcid":false,"given":"Ana","family":"Ascaso-del-Rio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garc\u00eda-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayte","family":"P\u00e9rez-Olmeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunate","family":"Arana-Arri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"P\u00e9rez-Ingidua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Castillo de la Osa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natale","family":"Imaz-Ayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Ria\u00f1o Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Astasio Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"D\u00edez-Fuertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Meijide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Arrizabalaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Hern\u00e1ndez Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humberto Erick","family":"de la Torre-Tarazona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mariano L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Vargas-Castrill\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0023-7377","authenticated-orcid":false,"given":"Jos\u00e9","family":"Alcam\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5646-5275","authenticated-orcid":false,"given":"Antonio","family":"Portol\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2022.101542_bib0001","doi-asserted-by":"crossref","unstructured":"European Centre for Disease Prevention and Control (ECDC), an agency of the European Union. SARS-CoV-2 variants of concern as of 27 January 2022. https:\/\/www.ecdc.europa.eu\/en\/covid-19\/variants-concern. Accessed 31 January 2022.","DOI":"10.2807\/1560-7917.ES.2022.27.7.2202171"},{"key":"10.1016\/j.eclinm.2022.101542_bib0002","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/vaccines9101195","article-title":"Emerging SARS-CoV-2 variants: a review of its mutations, its implications and vaccine efficacy","volume":"9","author":"Ramesh","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.eclinm.2022.101542_bib0003","unstructured":"European Centre for Disease Prevention and Control (ECDC). COVID-19 Vaccine Tracker.https:\/\/vaccinetracker.ecdc.europa.eu\/public\/extensions\/COVID-19\/vaccine-tracker.html#uptake-tab. Accessed 12 December 2021."},{"key":"10.1016\/j.eclinm.2022.101542_bib0004","unstructured":"European Medicines Agency (EMA). Comirnaty and Spikevax: EMA recommendations on extra doses and boosters. 2021. https:\/\/www.ema.europa.eu\/en\/news\/comirnaty-spikevax-ema-recommendations-extra-doses-boosters. Accessed 15 November 2021."},{"key":"10.1016\/j.eclinm.2022.101542_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2020.12.011","article-title":"COVID-19 vaccines: the status and perspectives in delivery points of view","volume":"170","author":"Chung","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.eclinm.2022.101542_bib0006","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2022.101542_bib0007","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2022.101542_bib0008","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101542_bib0009","doi-asserted-by":"crossref","first-page":"226","DOI":"10.7326\/M21-3480","article-title":"Neutralization of SARS-CoV-2 variants in transplant recipients after two and three doses of mRNA-1273 vaccine: secondary analysis of a randomized trial","volume":"175","author":"Kumar","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2022.101542_bib0010","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00508-021-01922-y","article-title":"Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: a phase 1 randomized clinical trial","volume":"133","author":"Kremsner","year":"2021","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.eclinm.2022.101542_bib0011","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1473-3099(21)00677-0","article-title":"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial","volume":"22","author":"Kremsner","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eclinm.2022.101542_bib0012","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMcibr2111445","article-title":"In gratitude for mRNA vaccines","volume":"385","author":"Stuart","year":"2021","journal-title":"N Engl J Med"},{"issue":"6572","key":"10.1016\/j.eclinm.2022.101542_bib0013","doi-asserted-by":"crossref","first-page":"abm0829","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.eclinm.2022.101542_bib0014","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.eclinm.2022.101542_bib0015","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2022.101542_bib0016","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients","volume":"385","author":"Kamar","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eclinm.2022.101542_bib0017","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study","volume":"9","author":"Hillus","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.eclinm.2022.101542_bib0018","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2022.101542_bib0019","article-title":"Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study","volume":"11","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.eclinm.2022.101542_bib0020","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","article-title":"Antibody evasion by the P.1 strain of SARS-CoV-2","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.eclinm.2022.101542_bib0021","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMc2114706","article-title":"Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum","volume":"385","author":"Uriu","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2022.101542_bib0022","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.eclinm.2022.101542_bib0023","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-021-04060-7","article-title":"Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination","volume":"600","author":"Cho","year":"2021","journal-title":"Nature"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022002723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022002723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:27:51Z","timestamp":1781526471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537022002723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":23,"alternative-id":["S2589537022002723"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101542","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101542","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101542"}}